key: cord-0029729-vnohzg3c
authors: Güleç, Özcan; Türkeş, Cüneyt; Arslan, Mustafa; Demir, Yeliz; Yeni, Yeşim; Hacımüftüoğlu, Ahmet; Ereminsoy, Ergün; Küfrevioğlu, Ömer İrfan; Beydemir, Şükrü
title: Cytotoxic effect, enzyme inhibition, and in silico studies of some novel N-substituted sulfonyl amides incorporating 1,3,4-oxadiazol structural motif
date: 2022-04-09
journal: Mol Divers
DOI: 10.1007/s11030-022-10422-8
sha: 2cffe7ab0160d3434be66e9874386429a4b09176
doc_id: 29729
cord_uid: vnohzg3c

ABSTRACT: The acetylcholinesterase and carbonic anhydrase inhibitors (AChEIs and hCAIs) remain key therapeutic agents for many bioactivities such as anti-Alzheimer and antiobesity antiepileptic, anticancer, antiinfective, antiglaucoma, and diuretic effects. Here, it has been attempted to discover novel multi-target AChEIs and hCAIs that are highly potent, orally bioavailable, may be brain penetrant, and have higher effectiveness at lower doses than tacrine and acetazolamide. After detailed investigations both in vitro and in silico, novel N-substituted sulfonyl amide derivatives (6a–j) were determined to be highly potent inhibitors for AChE and hCAs (K(I)s are in the range of 23.11–52.49 nM, 18.66–59.62 nM, and 9.33–120.80 nM for AChE, hCA I, and hCA II, respectively). Moreover, according to the cytotoxic effect studies, such as the ADME-Tox, cortex neuron cells, and neuroblastoma SH-SY5Y cell line, compounds 6a, 6d, and 6h, which are the most potent representative versus the target enzymes, were identified as orally bioavailable, highly selective, and brain preferentially distributed AChEIs and hCAIs. The docking studies revealed precise binding modes between 6a, 6d, and 6h and hCA II, hCA I, and AChE, respectively. The results presented here might provide a solid basis for further investigation into more potent AChEIs and hCAIs. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11030-022-10422-8.

Heterocyclic compounds play an essential role in medicinal chemistry. These agents are present in various drugs, most vitamins, many natural products, biomolecules, and biologically active compounds [1] [2] [3] [4] [5] [6] [7] . Oxadiazoles, an essential family of this class, have significant biological activities, such as analgesic, anti-inflammatory, anticonvulsive, antiemetic, fungicidal, diuretic, muscle relaxant, and antioxidant activity [8] [9] [10] . Oxadiazoles have different isomers. Among them, 1,3,4-oxadiazoles have become a significant construction motif for developing new drugs and have been determined to be more effective than other isomers in terms of biological activity. Compounds containing 1,3,4-oxadiazole cores, depending on the group of which it is a member, have a widespread biological activity spectrum, including antibacterial, antiviral, anticancer, antifungal, antihypertensive, analgesic, anticonvulsant, anti-inflammatory, and antidiabetic [11] . Due to this broad range of biological activities, the oxadiazole ring is used in various chemical reactions as a core part of a molecule. Moreover, many 1,3,4-oxadiazole motif-containing compounds are widely used in clinical medicine and drugs available in the market. For example, raltegravir, zibotentan, furamizole, and tiodazosin may be exhibited as antiretroviral [12] , anticancer [13] , antibacterial [14] , and antihypertensive agents [15] , respectively (Scheme S1).

Sulfonamides, which have strong pharmacological effects such as anticancer, antitumor, protease inhibitor, antibacterial, antifungal, antiprotozoal, anti-inflammatory, and anticonvulsants, have been used as medicines for nearly 100 years [16] [17] [18] [19] [20] [21] . Since the molecular structure of sulfonyl amides is similar to the structure of the p-aminobenzoic acid being synthesized in our body, it interferes with the reactions controlled by this agent and affects the functioning of the metabolism [22, 23] . The more acidic character of the hydrogens on the nitrogen of the N-substituted sulfonyl amides in this class causes it to form stronger hydrogen bonds and thus increase its activity [24] [25] [26] [27] [28] [29] (Scheme S2).

Alzheimer's disease (AD) is an age-related, complex, and multifactorial, chronic neurodegenerative disease which accounts for most cases of dementia. AD usually leads to cognitive dysfunction accompanied by some behaviors such as difficulty performing familiar tasks, memory loss, problems with language, anxiety, and depression. Many factors have been associated with AD development, and different hypotheses have been proposed, such as the cholinergic hypothesis, tau hypothesis, amyloid hypothesis, oxidative stress, and neuroinflammation. Although many potential drugs targeting these hypotheses have been tested to treat AD, there is no definitive cure. Acetylcholinesterase (AChE; EC 3.1.1.7) is currently one of the only well-validated molecular targets for AD [30, 31] . The AChE inhibitors (AChEIs) used in this direction decrease the hydrolysis of acetylcholine (ACh) into acetate and choline (Ch) and, with this, raise the ACh levels at the synaptic cleft that may stimulate cholinergic receptors and further promote memory function [32] [33] [34] . For example, AChE inhibitors such as tacrine, galantamine, rivastigmine, and donepezil remain the leading choice for treating AD today [35] .

Carbonic anhydrases (CAs; EC 4.2.1.1) [36] are zinc metalloenzymes [37] that activate the reversible reaction of bicarbonate ions and carbon dioxide in eukaryotes and prokaryotes [38] . CAs are contained in many crucial biosynthetic reactions, such as glucogenesis, lipogenesis, and ureagenesis. Moreover, they are also involved in numerous physiological processes like acid-base balance, electrolyte secretion, calcification, and transport of carbon dioxide and bicarbonate between tissues [39, 40] . hCA activators and/ or inhibitors (hCAIs) display many bioactivities containing anti-Alzheimer, antiobesity, antiepileptic, anticancer, antiinfective, antiglaucoma, and diuretic effects [41] . Therefore, hCA I (expressed in erythrocytes) and hCA II (expressed in testis, bone osteoclasts, brain, gastrointestinal tract, kidney, erythrocytes, eye, gastrointestinal tract, lung) among the isoenzymes in this class are the most studied ones.

In light of all this literature information, our current efforts were to design novel multi-target AChEIs and hCAIs, mainly aiming to decrease administration dose within the safety limits of commercially available drugs. In this direction, a novel series N-substituted sulfonyl amide derivative (6a-j) were designed, synthesized, characterized, and investigated the biological activities of these compounds on mentioned above target enzymes by this strategy. Because AChEIs generally have high cytotoxicity, the possibility that they may counteract their application as central nervous system-targeting therapeutics also has been considered. Therefore, this study also was investigated cytotoxicity and neurotoxicity profiles of compounds (6a, 6d, and 6h) being the most potent representative versus the enzymes mentioned above on the cortex neuron cells and neuroblastoma SH-SY5Y cell line. Additionally, in silico studies were performed to assess those inhibitors' inhibition mechanisms against AChE and hCAs.

General procedure for the preparation of the compounds Melting points were determined by a Yanagimoto micromelting point apparatus and are uncorrected. IR spectra were acquired on a SHIMADZU Prestige-21 (200 VCE) spectrometer. 1 H and 13 C NMR spectra were acquired at VAR-IAN Infinity Plus in 300 and 75 Hz, respectively. 1 H and 13 C chemical shifts are referenced to the internal deuterated solvent. The elemental analysis was carried out with a Leco CHNS-932 instrument. All chemicals were purchased from Sigma-Aldrich.

4-Sulfamoylbenzoic acid (10 mmol) was refluxed for 24 h in 50 mL of ethanol and 1.0 mL of sulfuric acid was used as a catalyst. At the end of the reaction, the solvent was evaporated and the obtained product was washed with cold water and dried.

Ethyl-4-(aminosulfonyl)benzoate (10 mmol) and hydrazine hydrate (25 mmol) in ethanol were refluxed for 24 h at 70 °C. The reaction mixture was cooled to room temperature and the solid was filtered then washed with water and dried.

Carbon sulfur (2.5 mmol) and 4-sulfonylamidebenzohydrazide (3) (1 mmol) were dissolved in DMF (6 mL) and K 2 CO 3 (1 mmol) was added to the mixture. Then, it was stirred for 12 h at room temperature. After the reaction was completed, the mixture was cooled to room temperature and poured into ice cold water. It was then filtered, dried, and crystallized.

Iodoethane (1.2 mmol) and 4-(5-thioxo-4,5-dihydro-1,3,4oxadiazol-2-yl)benzenesulfonamide (1 mmol) were dissolved in DMF (6 mL) and K 2 CO 3 (1 mmol) was added to the mixture, then, stirred for 12 h at room temperature. After the reaction was completed. The mixture was cooled to room temperature and poured into ice cold water. It was then filtered, dried, and crystallized.

Acylhalide derivatives (1.2 mmol) and 4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)benzenesulfonamide (1 mmol) were dissolved in pyridine (5 mL). Then, it was heated for 12 h at 60 °C. After the reaction was completed, the mixture was cooled to room temperature and poured into ice cold water. It was then filtered, dried, and crystallized from acetone. The prepared compounds shown in Scheme 1 were characterized by 1 H NMR, 13 C NMR, IR, and elemental analysis. 

Yield 72%, m.p. 142 °C. IR (ν max , cm −1 ): 3675 (N-H), 1708 (C=O), 1455 and 1385 (C-H), 1113 and 1106 (S=O). 1 

Yield 76%, m.p. 88 

In the present work, AChE from Electrophorus electricus (Sigma C2888) was purchased from Sigma-Aldrich Chemie GmbH. In vitro effects on AChE activity of the newly synthesized N-substituted sulfonyl amides (6a-j) incorporating 1,3,4-oxadiazol structural motif and reference compound, THA, were evaluated by the method of Ellman et al. [42, 43] . Analysis results were obtained spectrophotometrically at 412 nm using acetylthiocholine iodide (PubChem CID: 74629, Sigma 01480) as a substrate as in our previous assays [44, 45] . Also, hCAs (hCA I and II) were purified from human erythrocytes by Sepharose-4B-l-tyrosine-sulfanilamide affinity chromatography. The inhibition effects of these N-substituted sulfonyl amide derivatives (6a-j) and reference compound, AAZ versus the esterase activity of the hCAs were determined by following the change in absorbance at 348 nm according to the assay defined by Verporte et al. [46] [47] [48] . hCAs activities were measured using 4-nitrophenyl acetate (PubChem CID: 13,243, Sigma N8130). All the measurements were repeated thrice.

To investigate the in vitro inhibitory mechanisms of the novel synthesized N-substituted sulfonyl amides (6a-j) incorporating 1,3,4-oxadiazol structural motif, kinetic studies were made with the variable compound and substrate concentrations, and IC 50 curves, Michaelis-Menten graphs [49] [50] [51] , and Lineweaver-Burk curves [52] [53] [54] were generated as previously reported by Türkeş et al. [55] [56] [57] . Solutions of the novel synthesized all agents (6a-j), THA, and AAZ were prepared in dimethyl sulfoxide (PubChem CID: 679, Sigma D8418, DMSO) at an initial concentration of 1 mg/mL. The concentration of DMSO in the final reaction mixture was approx. 1%. IC 50 and K I values for these derivatives were computed from the observed data, and the types of inhibition of AChE and hCAs were determined as in our previous studies [58] [59] [60] . Analysis of the data and drawing of graphs were realized using GraphPad Prism version 8 for Mac (GraphPad Software, La Jolla California USA). The inhibition constants were calculated by SigmaPlot version 12 for Windows (Systat Software, San Jose California USA). The fit of enzyme inhibition models was compared using the extra sum-of-squares F test and Akaike's corrected information criterion approach. The results were exhibited as mean ± standard error of the mean (95% confidence intervals). Differences between data sets were considered statistically significant when the p value was less than 0.05.

The cortex neuron cells and neuroblastoma SH-SY5Y cell line was obtained from the Department of Medical Pharmacology, Faculty of Medicine, Atatürk University (Erzurum, Turkey). The cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 15% fetal bovine serum, and 1% antibiotic (penicillin, streptomycin, and amphotericin B), in a humidified atmosphere of 95% air and 5% CO 2 at 37 °C, and grown to 80% confluence [61, 62] . Before cell treatment, the complete medium was replaced with a reduced serum medium (i.e., with 2% fetal bovine serum). The novel synthesized N-substituted sulfonyl amide derivatives 6a, 6d, and 6h, which are the most potent representative versus the target enzymes, were prepared as stock solutions in DMSO at an initial concentration of 1 mg/mL. The cytotoxicity of these derivatives 6a, 6d, and 6h was compared with standard compound cisplatin. They were administered in four different doses (10, 100, 500, and 1000 µM) in a quadruplicate. After 24 h, on cortex neuron cells and SH-SY5Y cell line treated by seeding in 96-well plates with compounds 6a, 6d, and 6h, the administration was terminated, and the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) cytotoxicity test was performed. After the medium aspirating process of 10 μL, an MTT solution was added to each well. The plates containing the applications were kept for 4 h in an environment containing 5% CO 2 at 37 °C with MTT solution [63] . To dissolve the formazan crystals formed as a result of MTT, 100 μL DMSO was added to each well [64] . To determine the density of formazan crystals, data were obtained by reading plates with a Multiskan Go Microplate Spectrophotometer reader at a wavelength of 570 nm. Additionally, morphological changes occurring in the cortex neuron cells and SH-SY5Y cell line were visualized with an inverted microscope (Leica Microsystems, Wetzlar, Germany). The images obtained were recorded with × 200 magnification of the microscope [65] . GraphPad Prism version 8 for Mac (GraphPad Software, La Jolla California USA) was used for the statistical analyses to assess the results obtained in the study. The One-way ANOVA method was used to analyze the data, and the significance values were compared with the control group. Differences between data sets were considered statistically significant when the p value was less than 0.05.

In silico ADME-Tox assays were computed using Schrödinger Small-Molecule Drug Discovery Suite (Schrödinger Release 2021-1 panels for Mac: Maestro [66] , LigPrep [67] , QikProp [68, 69] ; Schrödinger, LLC, NY, USA) and SwissADME platform for the novel synthesized N-substituted sulfonyl amides (6a-j) incorporating 1,3,4-oxadiazol structural motif. The ligands (compounds 6a-j and the reference compounds, THA and AAZ) were firstly sketched using ChemDraw [70] , and PAINS alert [73] .

The potential modes of the binding of for the novel synthesized N-substituted sulfonyl amides (6a-j) [83] were applied for in silico molecular docking. The 4EY7, 6I0L, and 5NY3 in the crystal structures were minimized using the Protein Preparation Wizard tool [84] has been used for preparing the protein structure where bond orders were assigned and hydrogen atoms were added as well as restrained minimization step has also been done using optimized potential liquid simulations 4 (OPLS4) force field [85] at pH 7.4 ± 0.5 [86] . The active sites of theirs were predicted utilizing the SiteMap panel [87] . The ligand-binding sites were calculated using the Receptor Grid Generation tool [88] . LigPrep module was used for preparing all the synthesized N-substituted sulfonyl amides (6a-j) where bond order and the bond angle were assigned as well as minimization was done using OPLS4 force field [89] . The prepared small molecules were docked into the binding sites of the target enzymes by the Ligand Docking module with Glide extra precision (XP) mode [90] [91] [92] . MM-GBSA relative binding free energy computations [93] [94] [95] of target proteins (4EY7, 6I0L, and 5NY3) with the agents were carried out using the Prime tool in the VSGB energy model and OPLS4 force field [96, 97] .

Ethyl 4-(aminosulfonyl)benzoate was prepared from sulfamoylbenzoic acid in ethanol with catalytic amount of sulfuric acid by refluxing for 24 h. The ester group of the ethyl 4-(aminosulfonyl)benzoate was converted to 4-sulfonylamidebenzohydrazide with hydrazine hydrate in ethanol at 70 °C for 24 h. 4-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)benzene sulfonamide was prepared by reacting Carbon disulfur and 4-sulfonylamide benzohydrazide in DMF in the presence of K 2 CO 3 . 4-(5-(ethylthio)-1,3,4oxadiazol-2-yl) benzene sulfonamide was synthesized using Iodoethane and the compound 4 in DMF in basic condition. The final targeted compounds (6a-j) were prepared by acylhalide derivatives and the compound 5 in pyridine at 60 °C. The prepared compounds (6a-j) shown in Scheme 1 were characterized by 1 H NMR, 13 C NMR, IR, and elemental analysis. From the 1 H NMR spectra of the compounds, sulfanilamide NH resonances at very low field due to electron delocalization and the =CH proton peaks on aromatic ring come between 8.05 and 8.25 ppm. The signals of carbonyl and oxadiazole ring are seen at around 170 ppm and 165 ppm, respectively, in the 13 C NMR spectra. In the infrared spectra of compounds 6a-j, it was possible to observe the absorptions around 3660 cm −1 and 1700 cm −1 relating to N-H and C=O stretchings, respectively. As seen in the literature [98] , there are two peaks assigned to S=O as asymmetric and symmetric stretching which are appeared around 1300 and 1100 cm −1 , respectively. All spectra and elemental analyses support the structure of the synthesized compounds.

The hCAs and AChE inhibitory impact for all herein prepared target N-substituted sulfonyl amides (6a-j) incorporating 1,3,4-oxadiazol structural motif, as well as the standards, hCAI acetazolamide (AAZ; K I s for hCA I and hCA II 439.17 ± 9.30 and 98.28 ± 1.69 nM, respectively) and AChEI tacrine (THA; K I s for AChE 155.29 ± 0.82 nM), were estimated versus the ubiquitous cytosolic hCA I, II isoforms, and AChE by the use of the Verpoorte's and Ellman's methods, respectively. Certain structure-activity relationships (SAR) could be drawn from the shown inhibition data in Table 1 .

Regarding the hCAs inhibitory activities of N-substituted sulfonyl amides, all derivatives (6a-j) displayed potent inhibitory action against the ubiquitous cytosolic hCA I isoform with K I constants ranging from 18.66 ± 0.21 to 59.62 ± 0.53 nM (Table 1 ). In particular, N-substituted sulfonyl amide 6d (propyl substituted), 6a (phenyl substituted), and 6g (hexyl substituted) exhibited the best hCA I inhibitory activity with two-digit nanomolar activities with K I s equal 18.66 ± 0.21, 21.64 ± 0.25, and 23.01 ± 0.29 nm, respectively. Interestingly, the kinetic value of the compound 6d, which is the lowest in the series, displayed a 23.5-fold lower K I when compared to the reference AAZ (K I = 439.17 ± 9.30 nM). It is worth stressing that replacement of a propyl group (derivative 6d; K I = 18.66 ± 0.21 nM) with a tolyl group (derivative 6b; K I = 59.62 ± 0.53 nM) resulted in a more than threefold inhibition increase for the cytosolic hCA I isoform. On the other hand, it is determined that elongation of the sulfonyl acetamide linker in the butyl tail-bearing compound 6e (K I = 47.15 ± 0.36 nM) resulted in an increase in isoform hCA I inhibitory activity (derivatives 6f, 6g, 6h, 6i, and 6j; with K I s of 33.10 ± 0.47, 23.01 ± 0.29, 34.61 ± 0.51, 38.40 ± 0.46, and 31.01 ± 0.41 nM, respectively).

Moreover, exploring the inhibitory activity of herein reported N-substituted sulfonyl amide derivatives (6a-j) versus the physiologically dominant hCA II isoform revealed that it was effectively inhibited by sulfonyl amides (6a-j) with K I s spanning in the range 9.33 ± 0.13-120.80 ± 0.34 nM (Table 1) . Superiorly, compound 6a (phenyl substituted) exerted singledigit nanomolar inhibitory activity versus hCA II isoform (K I s = 9.33 ± 0.13 nM), thus resulting in 10.5-fold higher potency when compared to the reference AAZ (K I = 98.28 ± 1.69 nM), besides, compounds 6b, 6c, and 6d displayed K I constants close to each other 17.84 ± 0.23, 22.20 ± 0.22, and 23.18 ± 0.26 nM, respectively. Contrariwise, hCA II isoform was weakly inhibited by compounds 6h and 6i with K I s of 120.80 ± 0.34 and 112.70 ± 0.36 nM, respectively. It is worth mentioning that replacing the tolyl tail of derivative 6b (K I = 17.84 ± 0.23 nM) with a phenyl one, as in compound 6a, resulted in about twofold enhanced inhibitory potency against hCA II isoform (K I = 9.33 ± 0.13 nM). Furthermore, branching of the sulfonyl acetamide linker and its elongation decreased the hCA II inhibitory action for the heptyl tail-bearing derivative 6h. Moreover, it is worth highlighting that hCAIs profiles presented in Table 1 hinted out that compound 6b demonstrated interesting selectivity versus the ubiquitous cytosolic hCA I isoform (selectivity index; S I = 3.34), whereas compound 6h has shown selectivity against the dominant hCA II isoform (S I = 3.49). Hence, further structural modifications are required to optimize the hCA II/I selectivity. This selectivity for compounds 6b and 6h makes understand them as exciting and promising candidates for further improvement as potential hCAIs.

Recently, an increasing number of different hCAIs than the sulfonamides and their bioisosteres have been identified. In this context, the study by Sharma et al. [99] reported that two novel series of 1,3,4-oxadiazole benzenesulfonamide hybrids 3 and 4, having twenty novel compounds, have been designed and synthesized to assess their inhibition potential as hCAIs against hCA I, II, IX, and XII. They found that potent inhibitory activity versus hCA I has been exhibited by derivatives 3g and 4j, 3.5-fold of order better than standard drug AAZ and derivative 4j effectively inhibited glaucomaassociated hCA II isoform as well as tumor-associated hCA IX isoform. Rutkauskas et al. [100] reported that a series of N-aryl-β-alanine derivatives and diazobenzenesulfonamides containing aliphatic rings were designed, characterization, synthesized, and their binding to hCA I, II, VI, VII, XII, and XIII isoenzymes was studied using the fluorescent thermal shift assay and isothermal titration calorimetry. They determined that 4-substituted diazobenzenesulfonamides were more potent hCA binders than N-aryl-β-alanine derivatives.

The obtained inhibition constants for the AD-related AChE (Table 1) showed that all sulfonyl amides (6a-j) were capable of inhibiting this enzyme in the low nanomolar range (K I s of 23.11 ± 0.77-52.49 ± 1.27 nM). Derivatives 6f (pentyl substituted) and 6h (heptyl substituted) emerged as the most potent herein reported AChEI endowed with two-digit nanomolar K I values equal 39.34 ± 1.13 and 23.11 ± 0.77 nM, respectively (Table 1 ). In addition, the derivative 6h showed a K I value 6.7-fold higher when compared to the reference THA (K I = 155.29 ± 0.82 nM). Similar to the SAR for inhibition of hCA I; replacement of a tolyl group (compound 6b; K I = 47.03 ± 1.71 nM) with a heptyl group (compound 6h; K I = 23.11 ± 0.77 nM) was advantageous for inhibitory activity versus AChE. Also, elongation of the sulfonyl acetamide linker incorporated in the propyl tail-bearing derivative 6d was more beneficial for AChE inhibition (compound 6d; K I = 48.38 ± 1.75 nM), while the elongation of such linker resulted in about twofold increased activity versus AChE (compound 6h; K I = 23.11 ± 0.77 nM).

Because the cortex neuron cells and neuroblastoma SH-SY5Y cell line express one or more neurofilament proteins, specific norepinephrine uptake, and neuronal marker enzyme activity, since the early 1980s, it is commonly employed in experimental neurological studies, including metabolism, function, and neuronal differentiation analysis, connected to neuroprotection, neurotoxicity, neuroadaptive, and neurodegenerative processes [101] . Thus, to gain further insight into the therapeutic potential for the treatment for AD of these selected novel synthesized N-substituted sulfonyl amide derivatives 6a, 6d, and 6h incorporating 1,3,4-oxadiazol structural motif, which are the most potent representative versus the target enzymes, their cell viability, and proliferation activities were determined using the cortex neuron cells and neuroblastoma SH-SY5Y cell line. The colorimetric MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) was carried to examine the potential cytotoxic effects of these agents. Images of cortex neuron cells and SH-SY5Y cell line obtained by inverted microscope are given in Fig. 1 , respectively. The derivatives 6a, 6d, and 6h evaluated in our study caused a decrease in cell viability after 24 h of incubation, depending on the dose (IC 50 s = 0.95, 0.88, 0.82, and 0.64 µM for 6a, 0.99, 0.93, 0.87, and 0.74 µM for 6d, and 0.98, 0.92, 0.65, and 0.58 µM for 6h, in four different doses, 10, 100, 500, and 1000 µM, respectively). Moreover, they have been determined to display a propensity for high cell viability and neuroprotection at low concentrations (at 10 and 100 μM). However, these compounds showed cytotoxicities on the cortex neuron cells and neuroblastoma SH-SY5Y cells in a concentration-dependent manner, while N-substituted sulfonyl amide derivatives 6a, 6d, and 6h were found as non-toxic agents at their effective concentrations on target enzymes (AChE and hCAs) (Figs. 2 and 3) . Finally, when examining the information obtained in this study, 6a, 6d, and 6h compounds can be considered promising precursors for new design and development of therapeutics against AD. As a result, these agents exhibit that they have AChE inhibitory activity, which supports their use to treat neurological disorders.

All novel N-substituted sulfonyl amides (6a-j) incorporating 1,3,4-oxadiazol structural motif were evaluated in silico using the ADME-Tox prediction program QikProp, and SwissADME platform, and the findings are reported in Table 2 . All properties computed were satisfactory pharmacodynamic and pharmacokinetic properties for the novel synthesized N-substituted sulfonyl amide derivatives (6a-j). Additionally, diagrams showing "drug-likeness" Fig. 1 Inverted microscope images of compounds 6a, 6d, and 6h on cell viability in cortex neuron cells descriptors for 6a, 6d, and 6h agents, which are the most active derivatives in this series, are given in Fig. S1 . Only one (compound 6j) of all N-substituted sulfonyl amide derivatives (6a-j) were displayed one Lipinski's rule violation, and five agents (compounds 6b and 6g-j) showed only one Jorgensen's rule violation. Namely, computed in silico ADME-Tox properties confirmed newly synthesized these sulfonyl amides (6a-j) as hit agents displaying suitable drug-like properties. of E20, GZH, and 9E8 overlapped with the poses in the X-ray crystal structures of the AChE, hCA I, and hCA II at a root mean square deviation (RMSD) values of 0.62, 1.51, and 1.20 Å, respectively (Fig. 4) . These redocking assays were instrumental for selecting the best model structures that could host all the newly synthesized AChE, hCA I, and hCA II inhibitors, namely, novel N-substituted sulfonyl amide derivatives (6a-j). After that, the constructed binding model was used to perform docking calculations of the most potent AChE, hCA I, and hCA II inhibitors, compounds 6h, 6d, and 6a, respectively, in this series (6a-j) employing the Ligand Docking panel.

The predicted binding mode (docking score of − 7.34 kcal/mol and MM-GBSA value of − 49.23 kcal/ mol) between compound 6h and AChE showed that an H-bond interaction was generated between the oxygen atom of the sulfonamide moiety and Phe295 residue (distance of 2.25 Å). Also, Tyr124 (distance of 2.34 Å) made an H-bond with the carboxy group. However, both benzyl ring and oxadiazole-moiety stacked against Trp286 in the peripheral anionic site. Furthermore, hydrophobic interactions were monitored between derivative 6h and Tyr72, Ala204, Leu289, Val294, Phe297, Tyr337, Phe338, and Tyr341 residues (Fig. 5) . A docking score of − 4.10 kcal/ mol and MM-GBSA value of − 11.96 kcal/mol indicated that compound 6d is a tight binder for hCA I. A further look into the structural properties revealed agent 6d coordinated to the Zn(II) ion employing the deprotonated sulfonamide moiety, which in turn is involved in an H-bond interaction with the amide nitrogen of Thr200 (distance of 2.28 Å); further, the oxadiazole-moiety of derivative 6d displayed the strong H-bond involvement with Gln92 residue (distance of 2.60 Å). Moreover, it was exhibited that residues Phe91, Ala121, Leu131, Ala132, Ala135, Leu141, Val143, Leu198, Pro202, Val207, and Trp209 play significant roles in the binding of agent 6d with hCA I (Fig. 6) . One oxygen atom of the sulfonamide moiety of compound 6a (docking score of − 4.58 kcal/mol and MM-GBSA value of − 26.13 kcal/ mol) formed an H-bond with the Asn62 (distance of 2.76 Å), while the other oxygen atom made two H-bonds with the Asn67 and Gln92 (distances of 2.48 and 1.91 Å, respectively) from the binding site residues of hCA II. Also, the oxadiazole-moiety displayed π − π stacking interaction with Trp5 and His64. Additionally, compound 6a interacted with the hydrophobic pocket formed by Ala65, Val121, Leu141, Val143, Leu198, Pro201, Pro202, Val207, and Trp209, in the active site (Fig. 7) . Fig. 3 Cytotoxicity study of compounds 6a, 6d, and 6h on SH-SY5Y cells. The treatment of SH-SY5Y cells was performed with these groups at concentrations varying between 10 and 1000 μM. Every bar represents the mean ± standard error of the mean (95% confidence intervals) of three separate tests. A Viability rates for cortex neuron cells and B viability rates for neuroblastoma SH-SY5Y cell line Table 2 ADME-Tox-related parameters of novel synthesized N-substituted sulfonyl amides (6a-j) and standard inhibitors tacrine (THA), and acetazolamide (AAZ)

Various computational pharmacodynamic and pharmacokinetic parameters of synthesized compounds in this research were predicted such as molecular weight of the compound (MW), computed dipole moment of the compound (dipole), total solvent-accessible volume in cubic angstroms using a probe with a 1.4 Å radius (volume), octanol/gas partition coefficient (QPlogPoct), water/gas partition coefficient (QPlogPw), octanol/water partition coefficient (QPlogPo/w), aqueous solubility (QPlogS), apparent Caco-2 cell permeability in nm/sec (QPPCaco), brain/blood partition coefficient (QPlogBB), apparent MDCK cell permeability in nm/sec (QPPMDCK), skin permeability ( 

The small safety window of current AChEIs and hCAIs has limited their maximum therapeutic application in the therapy of some metabolic disorders, such as AD, epilepsy, cancer, and glaucoma. Here, we have attempted to design desirable novel multi-target AChEIs and hCAIs to overcome this deficiency. By this strategy, novel N-substituted sulfonyl amide derivatives (6a-j) were synthesized, and all of them displayed excellent inhibitory effects against AChE and hCAs. As expected, their effective doses were much lower than that of THA and AAZ, and in silico molecular docking studies on the X-ray co-crystal complexes for three highly potent derivatives (6a, 6d, and 6h) were provided precise binding modes between the individual agents and hCA II, hCA I, and AChE, respectively. Overall, according to both in silico ADME-Tox and cytotoxic effect studies on cortex neuron cells and neuroblastoma SH-SY5Y cell line were especially determined compounds 6a, 6d, and 6h be orally bioavailable, highly potent, and brain penetrant AChEIs and hCAIs. These favorable outcomes motivate us to detect further therapeutic values; more efforts for discovering novel multi-target AChEIs and hCAIs are currently underway. 

Heterocyclic chemistry in drug discovery

4-Thiazolidinones: the advances continue…

Synthesis and anti-mycobacterial activity of new 4-thiazolidinone and 1,3,4-oxadiazole derivatives of isoniazid

Study of novel anticancer 4-thiazolidinone derivatives

Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains

Synthesis, characterization and antimicrobial evaluation of 2, 5-disubstituted-4-thiazolidinone derivatives

Synthesis, antifungal and cytotoxic activities of 2-aryl-3-((piperidin-1-yl) ethyl) thiazolidinones

Synthesis, characterization and antibacterial evaluation of 1,3,4-oxadiazole derivatives

A review on the preparation of 1,3,4-oxadiazoles from the dehydration of hydrazines and study of their biological roles

Synthesis, characterization and antimicrobial screening of sulphonamide based 1, 3, 4-oxadiazoles

Oxadiazoles in medicinal chemistry

A historical sketch of the discovery and development of HIV-1 integrase inhibitors

Zibotentan endothelin ETA receptor antagonist oncolytic

In vitro sensitivity of mycoplasmas isolated from various animals and sewage to antibiotics and nitrofurans

Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables

Synthesis, antiproliferative activity and molecular docking studies of novel doubly modified colchicine amides and sulfonamides as anticancer agents

Synthesis and antitumor activity of new sulfonamide derivatives of thiadiazolo [3, 2-a] pyrimidines

Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (proteasehelicase/NTPase): a comparative study of different C-terminals

Cytotoxicity of multicellular cancer spheroids, antibacterial, and antifungal of selected sulfonamide derivatives coupled with a salicylamide and/or anisamide scaffold

Synthesis and biological evaluation of some new 2-pyrazolines bearing benzene sulfonamide moiety as potential anti-inflammatory and anti-cancer agents

Design, synthesis and pharmacological evaluation of novel N-(2-(1, 1-dimethyl-5, 7-dioxo-4, 6-diazaspiro[2.4]heptan-6-yl)ethyl) sulfonamide derivatives as potential anticonvulsant agents

The biosynthesis of folic acid IX. Purification and properties of the enzymes required for the formation of dihydropteroic acid

The biosynthesis of folic acid

In silico investigation and biological evaluation of synthesized sulfamethoxazole derivatives

Design, synthesis, antimicrobial evaluation and molecular docking studies of some new thiophene, pyrazole and pyridone derivatives bearing sulfisoxazole moiety

Accumulation characteristics and biological response of ginger to sulfamethoxazole and ofloxacin

Synthesis, characterization, biological evaluation and in silico studies of sulfonamide Schiff bases

Benzenesulfonamide derivatives as potent acetylcholinesterase, α-glycosidase, and glutathione S-transferase inhibitors: biological evaluation and molecular docking studies

Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors

Synthesis and bioactivities of 1-(4-hydroxyphenyl)-2-((heteroaryl) thio) ethanones as carbonic anhydrase I, II and acetylcholinesterase inhibitors

Synthesis, characterization, and inhibition study of novel substituted phenylureido sulfaguanidine derivatives as α-glycosidase and cholinesterase inhibitors

Novel benzoic acid derivatives: synthesis and biological evaluation as multi-target acetylcholinesterase and carbonic anhydrase inhibitors

Synthesis of N-alkylated pyrazolo[3,4-d] pyrimidine analogs and evaluation of acetylcholinesterase and carbonic anhydrase inhibition properties

Synthesis, biological evaluation and molecular docking of novel pyrazole derivatives as potent carbonic anhydrase and acetylcholinesterase inhibitors

Thiazolyl-pyrazoline derivatives: in vitro and in silico evaluation as potential acetylcholinesterase and carbonic anhydrase inhibitors

Calcium channel blockers: molecular docking and inhibition studies on carbonic anhydrase I and II isoenzymes

Synthesis of benzamide derivatives with thiourea-substituted benzenesulfonamides as carbonic anhydrase inhibitors

Sulfonamides incorporating ketene N,S-acetal bioisosteres as potent carbonic anhydrase and acetylcholinesterase inhibitors

Carbonic anhydrase, obstructive sleep apnea and hypertension: effects of intervention

Synthesis, biological evaluation and in silico studies of novel N-substituted phthalazine sulfonamide compounds as potent carbonic anhydrase and acetylcholinesterase inhibitors

Synthesis and in silico studies of triazene-substituted sulfamerazine derivatives as acetylcholinesterase and carbonic anhydrases inhibitors

A new and rapid colorimetric determination of acetylcholinesterase activity

The inhibition profile of sesamol against α-glycosidase and acetylcholinesterase enzymes

Aminoalkylated phenolic chalcones: investigation of biological effects on acetylcholinesterase and carbonic anhydrase I and II as potential lead enzyme inhibitors

Design, synthesis, characterization, in vitro and in silico evaluation of novel imidazo [2, 1-b][1, 3, 4] thiadiazoles as highly potent acetylcholinesterase and non-classical carbonic anhydrase inhibitors

Esterase activities of human carbonic anhydrases B and C

Inhibition profiles of voriconazole against acetylcholinesterase, α-glycosidase, and human carbonic anhydrase I and II isoenzymes

The toxicological effects of some avermectins on goat liver carbonic anhydrase enzyme

The original Michaelis constant: translation of the 1913 Michaelis-Menten paper

Calcium channel blockers: the effect of glutathione S-transferase enzyme activity and molecular docking studies

Synthesis, biological evaluation, and in silico study of novel library sulfonates containing quinazolin-4 (3H)-one derivatives as potential aldose reductase inhibitors

The determination of enzyme dissociation constants

Naphthoquinones, benzoquinones, and anthraquinones: Molecular docking, ADME and inhibition studies on human serum paraoxonase-1 associated with cardiovascular diseases

The effect of brimonidine and proparacaine on metabolic enzymes: glucose-6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and glutathione reductase

Effect of calcium channel blockers on paraoxonase-1 (PON1) activity and oxidative stress

Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium

In vitro inhibitory effects of palonosetron hydrochloride, bevacizumab and cyclophosphamide on purified paraoxonase-I (hPON1) from human serum

Synthesis and paroxonase activities of novel bromophenols

Anti-diabetic properties of calcium channel blockers: inhibition effects on aldose reductase enzyme activity

The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis

Nanotoxicity of magnesium oxide on human neuroblastoma SH-SY5Y cell lines

Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer

Vincristine combination with Ca+ 2 channel blocker increase antitumor effects

Preparation of CoS nanoparticles-cisplatin bio-conjugates and investigation of their effects on SH-SY5Y neuroblastoma cell line

The effects of MgS nanoparticles-Cisplatin-bio-conjugate on SH-SY5Y neuroblastoma cell line

Clobetasol propionate is a heme-mediated selective inhibitor of human cytochrome P450 3A5

Investigation of potential paraoxonase-I inhibitors by kinetic and molecular docking studies: chemotherapeutic drugs

Benzenesulfonamide derivatives containing imine and amine groups: inhibition on human paraoxonase and molecular docking studies

Synthesis, characterization, biological evaluation, and in silico studies of novel 1,3-diaryltriazene-substituted sulfathiazole derivatives

Some calcium-channel blockers: kinetic and in silico studies on paraoxonase-I

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Prediction of properties from simulations: free energies of solvation in hexadecane, octanol, and water

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

A potential risk factor for paraoxonase 1: in silico and in-vitro analysis of the biological activity of proton-pump inhibitors

Gadolinium-based contrast agents: in vitro paraoxonase 1 inhibition, in silico studies

Molecular docking and investigation of 4-(benzylideneamino)-and 4-(benzylamino)-benzenesulfonamide derivatives as potent AChE inhibitors

Mannich reaction derived novel boron complexes with amine-bis(phenolate) ligands: synthesis, spectroscopy and in vitro/in silico biological studies

New Isoindole-1, 3-dione substituted sulfonamides as potent inhibitors of carbonic anhydrase and acetylcholinesterase: design, synthesis, and biological evaluation

A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity

Structures of human acetylcholinesterase in complex with pharmacologically important ligands

Carbonic anhydrase inhibitors based on sorafenib scaffold: design, synthesis, crystallographic investigation and effects on primary breast cancer cells

Ranking power of the SQM/COSMO scoring function on carbonic anhydrase II-inhibitor complexes

In vitro and in silico studies on the toxic effects of antibacterial drugs as human serum paraoxonase 1 inhibitor

Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

Molecular docking and inhibition studies of vulpinic, carnosic and usnic acids on polyol pathway enzymes

Inhibition of human serum paraoxonase-I with antimycotic drugs: in vitro and in silico studies

Identifying and characterizing binding sites and assessing druggability

Synthesis, characterization, inhibition effects, and molecular docking studies as acetylcholinesterase, α-glycosidase, and carbonic anhydrase inhibitors of novel benzenesulfonamides incorporating 1,3,5-triazine structural motifs

Novel metabolic enzyme inhibitors designed through the molecular hybridization of thiazole and pyrazoline scaffolds

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes

Molecular docking studies and inhibition properties of some antineoplastic agents against paraoxonase-I. Anti-Cancer

Towards more effective acetylcholinesterase inhibitors: a comprehensive modelling study based on human acetylcholinesterase protein-drug complex

Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring

Transition-metal complexes of bidentate Schiff-base ligands: in vitro and in silico evaluation as non-classical carbonic anhydrase and potential acetylcholinesterase inhibitors

Infection medications: assessment In-vitro glutathione S-transferase inhibition and molecular docking study

Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies

Synthesis and evaluation of sulfonamide-bearing thiazole as carbonic anhydrase isoforms hCA I and hCA II

Tail approach synthesis of novel benzenesulfonamides incorporating 1, 3, 4-oxadiazole hybrids as potent inhibitor of carbonic anhydrase I, II, IX, and XII isoenzymes

4-amino-substituted benzenesulfonamides as inhibitors of human carbonic anhydrases

SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease

The authors declare that there is no conflict of interest.